...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of molecular diagnostics: JMD >Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.
【24h】

Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.

机译：使用COBAS AmpliPrep总核酸分离和COBAS taqman丙型肝炎病毒分析物特异性试剂进行定量丙型肝炎病毒RNA测定的性能特征。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Performance characteristics of a hepatitis C virus (HCV) RNA quantification assay comprised automated specimen extraction [COBAS AmpliPrep (CAP) using total nucleic acid isolation reagents (TNAI)], and real-time polymerase chain reaction [COBAS TaqMan 48 HCV with analyte-specific reagents (CTM48)] were determined. CAP TNAI/CTM48 performed linearly from approximately 2.0 to at least 6.7 log10 IU/ml for HCV genotypes (Gts) 1, 2, and 3. The limit of detection for the World Health Organization International Standard was 23 IU/ml. Variabilities ranged from 1.3 to 2.1%. Excellent quantitative agreement was observed in clinical samples using CTM48 and two different methods for HCV RNA extraction (CAP TNAI and BioRobot M48; regression line slope, 0.98; y-intercept, 0.11; R2, 0.98; mean difference, 0.003). Good agreement was also observed between CAP TNAI/CTM48 and COBAS Amplicor Monitor (regression line slope, 0.94; y-intercept, 0.08; R2, 0.96), although HCV RNA concentrations were on average greater by COBAS Amplicor Monitor (mean difference -0.27 log10 IU/ml). Better overall agreement was observed for Gt 1 than non-Gt 1 specimens when comparing extraction and quantification methods; however, no consistent genotype-dependent quantification bias was observed. These data suggest that CAP TNAI/CTM48 offers an alternative method for the quantification of HCV in plasma samples.
机译：丙型肝炎病毒（HCV）RNA定量分析的性能特征包括自动标本提取[使用总核酸分离试剂（TNAI）的COBAS AmpliPrep（CAP）]和实时聚合酶链反应[COBAS TaqMan 48 HCV，具有分析物特异性测定试剂（CTM48）。对于HCV基因型（Gts）1、2和3，CAP TNAI / CTM48从大约2.0到至少6.7 log10 IU / ml线性执行。世界卫生组织国际标准的检出限为23 IU / ml。变异范围为1.3％至2.1％。使用CTM48和两种不同的HCV RNA提取方法（CAP TNAI和BioRobot M48;临床回归线斜率0.98; y截距0.11; R2 0.98;平均差0.003）在临床样品中观察到了极好的定量一致性。在CAP TNAI / CTM48和COBAS Amplicor Monitor之间也观察到良好的一致性（回归线斜率，0.94; y截距，0.08; R2，0.96），尽管COBAS Amplicor Monitor平均HCV RNA浓度更高（均值-0.27 log10 IU / ml）。比较提取和定量方法时，与非Gt 1样品相比，Gt 1的总体一致性更好。但是，没有观察到一致的基因型依赖性定量偏差。这些数据表明，CAP TNAI / CTM48提供了另一种定量血浆样品中HCV的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号